A progesterone vaginal insert has been OK'd for marketing and will be sold under the name Endometrin, from Ferring Pharmaceuticals. The new formulation will be available in a100-mg strength and is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an assisted reproductive technology treatment for infertile women.
A progesterone vaginal insert has been OK'd for marketing and will be sold under the name Endometrin, from Ferring Pharmaceuticals. The new formulation will be available in a100-mg strength and is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an assisted reproductive technology treatment for infertile women. According to the manufacturer, Endometrin is the first new form of progesterone supplementation in a decade and is administered two to three times daily starting at oocyte retrieval and continuing for up to 10 weeks' total duration. Prior to this approval, progesterone has been available in oral, intramuscular injection, vaginal gel, and suppository forms.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.